Nilotinib Teva

Nilotinib, the active ingredient in Nilotinib Teva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of adult patients with Philadelphia chromosome‑positive chronic myeloid leukemia (CML) across disease phases. It works by blocking the BCR‑ABL tyrosine kinase, thereby inhibiting leukemic cell proliferation.

GNH USA supplies Nilotinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under GMP conditions.

Nilotinib targets the BCR‑ABL driven pathway in chronic myeloid leukemia, providing disease control across its phases. - Chronic myeloid leukemia (chronic phase): reduces leukemic cell burden and helps achieve cytogenetic and molecular remission. - Chronic myeloid leukemia (accelerated phase): improves disease control and delays progression. - Chronic myeloid leukemia (blast phase): contributes to reduction of blast cells and supports remission when combined with other therapies.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash - Headache - Fatigue - Arthralgia

Serious or Rare Side Effects: - QT interval prolongation and cardiac arrhythmias - Arterial occlusive events (e.g., peripheral arterial disease) - Severe liver injury (hepatitis, elevated transaminases) - Pancreatitis - Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis) - Tumor lysis syndrome

When prescribing nilotinib, clinicians should observe several precautionary measures to minimize risk. - Monitor cardiac function: obtain baseline ECG and repeat periodically to detect QT prolongation. - Assess hepatic function: check liver enzymes before initiation and during therapy. - Check electrolyte levels: especially potassium and magnesium, correcting abnormalities before treatment. - Avoid strong CYP3A4 inhibitors: concomitant use may increase nilotinib exposure and toxicity. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Nilotinib interacts with several medicines; understanding the interaction level guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase plasma concentrations. - Antacids containing aluminum or magnesium: reduce nilotinib absorption if taken simultaneously. - QT‑prolonging agents (e.g., sotalol, amiodarone): increase risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib exposure and reduce efficacy. - Warfarin: may require closer INR monitoring due to potential interaction. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): monitor for myopathy and adjust dose if needed.